Nasdaq- and JSE-listed advanced materials company ASP Isotopes (ASPI) says all its business units are making considerable progress, group revenues are increasing and three of its business units are at an inflection point and expected to make substantial contributions to achieving profitability in the near term.
In an update to shareholders before the publication of the company's second-quarter financial results, ASPI CEO and executive chairperson Paul Mann says the two divisions responsible for the majority of near to mid-term earnings before interest, taxes, depreciation and amortisation (Ebitda) targets, namely radiopharmaceutical production company PET Labs and liquefied helium (LHe) and liquefied natural gas (LNG) producer Renergen, are operating ahead of internal expectations in terms of timing and potential profitability.
This reinforces ASPI's confidence in its 2031 Ebitda target of greater than $300-million, with the range for Ebitda by 2031 expected to be between $330-million and $700-million.
“We are currently negotiating helium and hydrocarbon supply contracts with potential large global customers on 5- to 15-year take-or-pay arrangements, which gives us considerable visibility over our expected future revenues,” he says.
